CytoMed Therapeutics (NASDAQ: GDTC) CFO reports holding 25,781 ordinary shares

Rhea-AI Filing Summary

CytoMed Therapeutics Ltd filed an initial insider ownership report for its Chief Financial Officer, Yvonne Goh. The filing shows she directly holds 25,781 Ordinary Shares of the company. This Form 3 does not report any new share purchases, sales, or option exercises, only her existing stake.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Goh Yvonne

Role Chief Financial Officer

Type	Security	Shares	Price	Value
holding	Ordinary Shares, no par value per share	--	--	--

Holdings After Transaction: Ordinary Shares, no par value per share — 25,781 shares (Direct, null)

Footnotes (1)

Key Figures

Direct shareholding: 25,781 Ordinary Shares

1 metrics

Direct shareholding 25,781 Ordinary Shares Total shares following reported position for CFO Yvonne Goh

Key Terms

Form 3, Ordinary Shares, no par value per share, Chief Financial Officer

3 terms

Form 3 regulatory

"CytoMed Therapeutics Ltd filed an initial insider ownership report"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Ordinary Shares, no par value per share financial

"The filing shows she directly holds 25,781 Ordinary Shares"

Chief Financial Officer financial

"for its Chief Financial Officer, Yvonne Goh"

A Chief Financial Officer (CFO) is the person in charge of a company's money and financial planning. They decide how to spend, save, and invest funds to help the company grow and stay stable. Their role is important because good financial decisions keep the company healthy and successful.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Goh Yvonne

(Last) (First) (Middle)

C/O CYTOMED THERAPEUTICS LIMITED

1 COMMONWEALTH LANE #08-22

(Street)

SINGAPORE 149544

(City) (State) (Zip)

SINGAPORE

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
CytoMed Therapeutics Ltd [ GDTC ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares, no par value per share	25,781	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Yvonne Goh	05/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does CytoMed Therapeutics (GDTC) CFO Yvonne Goh’s Form 3 show?

The Form 3 shows that CytoMed Therapeutics CFO Yvonne Goh directly holds 25,781 Ordinary Shares. This is an initial ownership report and does not disclose any recent purchases, sales, or option exercises, only her existing stake in the company.

Is CytoMed Therapeutics (GDTC) CFO buying or selling shares in this Form 3?

No, this Form 3 for CytoMed Therapeutics CFO Yvonne Goh does not report any share purchases or sales. It simply records her direct ownership of 25,781 Ordinary Shares as required when an insider’s holdings are first reported.

How many CytoMed Therapeutics (GDTC) shares does CFO Yvonne Goh own?

According to the Form 3, CFO Yvonne Goh directly owns 25,781 Ordinary Shares of CytoMed Therapeutics. The filing lists this as her total direct holdings following the reported position, with no derivative securities disclosed.

What type of security does CytoMed Therapeutics CFO report in the Form 3?

The Form 3 lists Ordinary Shares, no par value per share as the security held by CytoMed Therapeutics CFO Yvonne Goh. She reports total direct ownership of 25,781 Ordinary Shares, with no additional derivative positions included in this filing.

Does the CytoMed Therapeutics (GDTC) Form 3 for the CFO include derivative securities?

No, the Form 3 for CytoMed Therapeutics CFO Yvonne Goh does not list any derivative securities such as options or warrants. It only reports a direct holding of 25,781 Ordinary Shares, with no additional derivative positions shown in the derivative summary.